CIA
KYMR icon

Capital Impact Advisors’s Kymera Therapeutics KYMR Stock Holding History

Capital Impact Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,889
Closed -$960K – 78
2024
Q1 		$960K Hold
23,889
– – 1.25% 28
2023
Q4 		$608K Buy
+23,889
New +$427K 0.8% 63

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Capital Impact Advisors's KYMR Position: Q2 2024 in Review

Capital Impact Advisors sold out of Kymera Therapeutics (KYMR) in Q2 2024, closing a stake of 23,889 shares — an estimated $960K sold.

Capital Impact Advisors first reported a position in KYMR in Q4 2023 and held it in 2 quarters. The position peaked at $960K in Q1 2024. 157 funds tracked by Wall St. Rank hold KYMR as of Q2 2024.

  • Capital Impact Advisors reported no remaining Kymera Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 23,889 Kymera Therapeutics shares in Q2 2024, an estimated $960K.
  • Capital Impact Advisors first reported a position in Kymera Therapeutics in Q4 2023 and held it in 2 quarters.
  • Capital Impact Advisors's Kymera Therapeutics position peaked at $960K in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2024.

Based on Capital Impact Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.